Introducing the 2019 ESC Guidelines on Diabetes, Pre-Diabetes, and CVD

Autor: Victor Aboyans
Přispěvatelé: Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Service de cardiologie [CHU Limoges], CHU Limoges
Rok vydání: 2019
Předmět:
cardiovascular risk factors
physical activity
0302 clinical medicine
underweight
Risk Factors
MESH: Peripheral Arterial Disease
Medicine
MESH: Obesity
030212 general & internal medicine
rivaroxaban
Body mass index
MESH: Aged
Secondary prevention
blood pressure
Diabetes mellitus therapy
3. Good health
Pre diabetes
Cardiovascular Diseases
Practice Guidelines as Topic
Cardiology and Cardiovascular Medicine
Risk assessment
African population
medicine.medical_specialty
MEDLINE
030209 endocrinology & metabolism
peripheral artery disease
Risk Assessment
smoking
MESH: Body Mass Index
Diabetes Complications
Prediabetic State
03 medical and health sciences
Diabetes mellitus
Internal medicine
Diabetes Mellitus
Humans
Hypoglycemic Agents
MESH: Overweight
MESH: Prevalence
MESH: Humans
MESH: Thinness
business.industry
cholesterol
Anticoagulants
medicine.disease
MESH: Male
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
business
MESH: Female
Platelet Aggregation Inhibitors
Zdroj: European Heart Journal
European Heart Journal, Oxford University Press (OUP): Policy B, 2019, 40 (39), pp.3217-3219. ⟨10.1093/eurheartj/ehz688⟩
ISSN: 1522-9645
0195-668X
DOI: 10.1093/eurheartj/ehz688⟩
Popis: International audience; Secondary prevention in patients with coronary artery disease and peripheral artery disease involves antithrombotic therapy and optimal control of cardiovascular risk factors. In the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) study, adding low-dose rivaroxaban on top of aspirin lowered cardiovascular events, but there is limited data about risk factor control in secondary prevention. We studied the association between risk factor status and outcomes, and the impact of risk factor status on the treatment effect of rivaroxaban, in a large contemporary population of patients with coronary artery disease or peripheral artery disease.
Databáze: OpenAIRE
Externí odkaz: